CIRRH
MCID: LVR012
MIFTS: 62

Liver Cirrhosis (CIRRH)

Categories: Gastrointestinal diseases

Aliases & Classifications for Liver Cirrhosis

MalaCards integrated aliases for Liver Cirrhosis:

Name: Liver Cirrhosis 12 73 54 44 15 37 70
Cirrhosis 12 72 54 42 15 39 70
Cirrhosis of Liver 12 29 6 17
Cirrhosis, Cryptogenic 70
Cryptogenic Cirrhosis 72
Cirrh 72

Classifications:



External Ids:

Disease Ontology 12 DOID:5082
MeSH 44 D008103
NCIt 50 C2951
SNOMED-CT 67 19943007
ICD10 32 K74.60
UMLS 70 C0023890 C0267809 C1623038

Summaries for Liver Cirrhosis

MedlinePlus : 42 Cirrhosis is scarring of the liver. Scar tissue forms because of injury or long-term disease. Scar tissue cannot do what healthy liver tissue does - make protein, help fight infections, clean the blood, help digest food and store energy. Cirrhosis can lead to Easy bruising or bleeding, or nosebleeds Swelling of the abdomen or legs Extra sensitivity to medicines High blood pressure in the vein entering the liver Enlarged veins called varices in the esophagus and stomach. Varices can bleed suddenly. Kidney failure Jaundice Severe itching Gallstones A small number of people with cirrhosis get liver cancer. Your doctor will diagnose cirrhosis with blood tests, imaging tests, or a biopsy. Cirrhosis has many causes. In the United States, the most common causes are chronic alcoholism and hepatitis. Nothing will make the scar tissue disappear, but treating the cause can keep it from getting worse. If too much scar tissue forms, you may need to consider a liver transplant. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Liver Cirrhosis, also known as cirrhosis, is related to alcoholic liver cirrhosis and primary biliary cholangitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Cirrhosis is KRT8 (Keratin 8), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and FOXA2 and FOXA3 transcription factor networks. The drugs Zinc and Propofol have been mentioned in the context of this disorder. Affiliated tissues include Bone and Blood.

UniProtKB/Swiss-Prot : 72 Cirrhosis: A liver disease characterized by severe panlobular liver-cell swelling with Mallory body formation, prominent pericellular fibrosis, and marked deposits of copper. Clinical features include abdomen swelling, jaundice and pulmonary hypertension.

Wikipedia : 73 Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, and end-stage liver disease, is the... more...

Related Diseases for Liver Cirrhosis

Diseases related to Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1583)
# Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 33.7 HGF GPT F2 CYP2E1 ALB AFP
2 primary biliary cholangitis 33.3 GPT GGT1 F2 ALB
3 hepatic encephalopathy 32.9 GPT F2 ALB
4 portal hypertension 32.7 GPT F2 ALB
5 hepatic coma 32.7 GPT F2 ALB AFP
6 cholangitis, primary sclerosing 32.6 SERPINA1 GPT GGT1 F2 ALB AFP
7 hepatitis 32.6 KRT8 KRT18 IFNA1 GPT GGT1 F2
8 esophageal varix 32.6 SERPINA1 GPT F2 ALB AFP
9 budd-chiari syndrome 32.5 F2 ALB AFP
10 hepatitis b 32.4 IFNA1 GPT GGT1 F2 ALB AFP
11 hepatorenal syndrome 32.3 GPT F2 ALB
12 cryptogenic cirrhosis 32.2 LOC106096416 KRT8 KRT18 HFE F2
13 alcohol use disorder 32.2 HFE GPT GGT1 CYP2E1 ALB
14 portal vein thrombosis 32.2 IFNA1 F2 AFP
15 hypersplenism 32.1 GPT F2 ALB
16 viral hepatitis 32.1 SERPINA1 KRT8 KRT18 IFNA1 HFE GPT
17 cholestasis 32.0 SERPINA1 GPT GGT1 F2 ALB
18 liver disease 31.9 SERPINA1 MEG3 KRT8 KRT18 IFNA1 HGF
19 non-alcoholic fatty liver disease 31.9 SERPINA1 KRT18 HFE GPT GGT1 CYP2E1
20 cholangitis 31.9 GPT GGT1 F2 ALB
21 hemochromatosis, type 1 31.8 SERPINA1 HFE GPT ALB AFP
22 acute kidney failure 31.8 HGF GPT F2 ALB
23 non-alcoholic steatohepatitis 31.8 KRT18 HGF HFE GPT CYP2E1 ALB
24 alpha-1-antitrypsin deficiency 31.8 SERPINA1 HFE GPT F2 ALB AFP
25 hepatitis c 31.8 KRT8 KRT18 IFNA1 HOTAIR HFE GPT
26 hemosiderosis 31.7 HFE GPT ALB
27 bilirubin metabolic disorder 31.7 SERPINA1 GPT GGT1 F2 CYP2E1 ALB
28 alcoholic hepatitis 31.7 KRT18 HGF GPT GGT1 F2 CYP2E1
29 deficiency anemia 31.6 IFNA1 HFE GPT F2 ALB
30 fatty liver disease 31.6 MALAT1 KRT18 HFE GPT GGT1 CYP2E1
31 sclerosing cholangitis 31.6 GPT GGT1 F2 ALB
32 obstructive jaundice 31.6 HGF GPT GGT1 F2 ALB
33 autoimmune hepatitis 31.6 KRT8 KRT18 IFNA1 GPT GGT1 F2
34 schistosomiasis 31.6 GPT F2 ALB
35 pleural empyema 31.5 GPT F2 ALB
36 respiratory failure 31.5 SERPINA1 GPT F2 ALB
37 hepatitis a 31.5 SERPINA1 IFNA1 GPT F2 ALB AFP
38 cholecystitis 31.4 KRT18 GPT F2 ALB
39 acute liver failure 31.4 HGF GPT F2
40 exanthem 31.4 IFNA1 GPT F2 ALB
41 acute cystitis 31.4 GPT F2 ALB
42 acute kidney tubular necrosis 31.4 HGF GPT F2 ALB
43 choledocholithiasis 31.4 GPT GGT1 F2 ALB
44 hepatitis d 31.4 IFNA1 GPT F2
45 type 2 diabetes mellitus 31.4 HGF HFE GPT GGT1 GAS5 F2
46 siderosis 31.3 SERPINA1 HFE GPT
47 biliary atresia 31.3 HGF GPT GGT1 F2 ALB
48 hepatitis e 31.3 GPT F2 ALB
49 tricuspid valve insufficiency 31.2 GPT F2 ALB
50 cellulitis 31.2 GPT F2 ALB

Graphical network of the top 20 diseases related to Liver Cirrhosis:



Diseases related to Liver Cirrhosis

Symptoms & Phenotypes for Liver Cirrhosis

UMLS symptoms related to Liver Cirrhosis:


nausea and vomiting; constipation; abdominal pain; diarrhea; hepatosplenomegaly; dyspepsia; icterus; heartburn; gastrointestinal gas

Drugs & Therapeutics for Liver Cirrhosis

Drugs for Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 591)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6 32051
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Magnesium oxide Approved Phase 4 1309-48-4 14792
5
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
6
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
7
Azithromycin Approved Phase 4 83905-01-5 447043 55185
8
Vancomycin Approved Phase 4 1404-90-6 14969 441141
9
Insulin glargine Approved Phase 4 160337-95-1
10
Insulin glulisine Approved Phase 4 207748-29-6
11
acetic acid Approved Phase 4 64-19-7 176
12
Colchicine Approved Phase 4 64-86-8 6167 2833
13
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
14
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
15
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
16
Cefoxitin Approved Phase 4 35607-66-0 441199
17
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
18
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
19
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
20
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
21
Canrenoic acid Approved, Withdrawn Phase 4 4138-96-9
22
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
23
Nadolol Approved Phase 4 42200-33-9 39147
24
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
25
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
26
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
27
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
28
Losartan Approved Phase 4 114798-26-4 3961
29
Abatacept Approved Phase 4 332348-12-6 10237
30
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
31
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
32
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
33
Ledipasvir Approved Phase 4 1256388-51-8 67505836
34
Methylene blue Approved, Investigational Phase 4 61-73-4
35
Nevirapine Approved Phase 4 129618-40-2 4463
36
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
37
Meperidine Approved Phase 4 57-42-1 4058
38
Nadroparin Approved, Investigational Phase 4
39
Octreotide Approved, Investigational Phase 4 83150-76-9 6400441 383414
40
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
41
Iron Approved Phase 4 7439-89-6 23925 29936
42
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
43
Nitric Oxide Approved Phase 4 10102-43-9 145068
44
Atorvastatin Approved Phase 4 134523-00-5 60823
45
Warfarin Approved Phase 4 81-81-2 54678486 6691
46
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
47
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
48
Pentetic acid Approved Phase 4 67-43-6
49
Edetic Acid Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
50
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610

Interventional clinical trials:

(show top 50) (show all 1521)
# Name Status NCT ID Phase Drugs
1 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
2 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
3 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
4 A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
5 Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Unknown status NCT02074280 Phase 4 rifaximin
6 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
7 Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
8 Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis - a Prospective Randomized Long-Term Study Unknown status NCT00239096 Phase 4 losartan (drug)
9 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
10 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
11 A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
12 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
13 Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems Unknown status NCT00332904 Phase 4 propranolol;spironolactone
14 The Effect of Carvedilol Vs Propranolol in Patients With Cirrhosis Related Esophagogastric Varices After Multiple Endoscopic Treatments For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
15 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
16 Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Comparing Carvedilol and Endoscopic Therapy: A Multicenter Randomized Controlled Trial Unknown status NCT02695732 Phase 4 Carvedilol
17 Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
18 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
19 A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
20 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial Unknown status NCT01298284 Phase 4 propranolol
21 A Multi-Center Study to Assess the Efficacy and Safety of Traditional Chinese Medicine Combined With Entecavir for Patients With Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV Unknown status NCT02241616 Phase 4 Entecavir+Fuzheng Huayu+TCM Granule
22 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
23 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
24 Rifaximin Reduces the Complications of Decompensated Cirrhosis Unknown status NCT02190357 Phase 4 Rifaximin
25 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
26 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Unknown status NCT02401490 Phase 4 Human albumin;Placebo
27 Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial Unknown status NCT01282398 Phase 4 Simvastatin;placebo
28 The Effect of HVPG-Guided Individualized Therapy in Patients With Cirrhosis Related Esophagogastric Variceal Hemorrhage For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02638415 Phase 4 Carvedilol
29 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
30 The Employing of the Bio-Hep-B PreS1/PreS2/S Hepatitis B Virus (HBV) Vaccine in New Born Babies From HBV Positive Palestinian Mothers Unknown status NCT01133184 Phase 4
31 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
32 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
33 A Randomized Controlled Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Unknown status NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
34 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
35 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
36 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Unknown status NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
37 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial Unknown status NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
38 Propofol and Fentanyl Versus Midazolam and Fentanyl for Sedation During Diagnostic or Therapeutic Gastrointestinal Endoscopy in Cirrhotic Patients Unknown status NCT00906139 Phase 4 Propofol;Midazolam;Fentanyl
39 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Unknown status NCT01530711 Phase 4 Terlipressin and albumin
40 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
41 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
42 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
43 The Protection of Telipression on Developing of Acute Kidney Injury in Cirrhotic Patients With Upper-gastroentestinal Bleeding Completed NCT04358016 Phase 4 Terlipressin;Somatostatin
44 Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis Completed NCT01265173 Phase 4 Cefotaxime;Ceftriaxone;Ciprofloxacin
45 Prospective Detection of Liver Fibrosis With MRI Compared to Fibroscan and Blood Tests Completed NCT01600105 Phase 4 Perfusion MRI
46 Phase IV Study of Long Term Peg-Intron for Patients Who Have Failed to Respond to Rebetron/Interferon With Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C- The Copilot Trial Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
47 The Effect of Oral Taurine on Portal Hemodynamics in Patients With Advanced Completed NCT02344719 Phase 4 Taurin 6g per day per oral for 28 days;Placebo 6g per day per oral for 28 days
48 Phase 4 Study on the Comparison Between Combined Versus Sequential Diuretic Treatment of Moderate Ascites in Nonazotemic Patients With Cirrhosis Completed NCT00741663 Phase 4 Spironolactone and furosemide;Spironolactone and furosemide
49 LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial Completed NCT01847651 Phase 4 LOLA or placebo
50 Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo

Search NIH Clinical Center for Liver Cirrhosis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Bumetanide
Ethacrynate Sodium
Ethacrynic Acid
Furosemide
Milk thistle extract
torsemide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Cirrhosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Cirrhosis:
Autologous bone marrow-derived mesenchymal stem cells for liver cirhosis
Autologous bone marrow-derived stem cells for treatment of liver cirrhosis
Autologous hematopoietic stem cells for treatment of end-stage chronic liver disease
Bone marrow-derived endothelial progenitor cells for advanced liver cirrhosis
Bone marrow-derived mesenchymal stem cells for treatment of cirrhosis-related refractory ascites
Bone marrow-derived mesenchymal stem cells for treatment of liver cirrhosis
Hepatocyte transplantation for treatment of liver failure and inherited metabolic diseases
Mesenchymal stem cells for liver cirrhosis
NU215-01, human umbilical cord mesenchymal stem cells for treatment of liver cirrhosis
Peripheral blood-derived CD34+ or mononuclear cells for liver cirrhosis
StempeucelLC, mesenchymal stem cells for liver cirrhosis
Umbilical cord-derived mesenchymal stem cells for treatment of liver cirrhosis
Embryonic/Adult Cultured Cells Related to Liver Cirrhosis:
Bone marrow-derived mesenchymal stem cells (family) PMIDs: 22121493 21771778
Peripheral blood-derived hematopoietic stem cells PMIDs: 20587151
Bone marrow-derived endothelial progenitor cells (family)
Hepatocytes
Umbilical cord-derived mesenchymal stem cells
Peripheral blood-derived hematopoietic stem cells (family)
Peripheral blood-derived mesenchymal stem cells (family)
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 18720444
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver cirrhosis

Genetic Tests for Liver Cirrhosis

Genetic tests related to Liver Cirrhosis:

# Genetic test Affiliating Genes
1 Cirrhosis of Liver 29

Anatomical Context for Liver Cirrhosis

MalaCards organs/tissues related to Liver Cirrhosis:

40
Liver, Bone Marrow, Spleen, Bone, Kidney, Endothelial, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Liver Cirrhosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
3 Liver Sinusoids Hepatic Stellate Cells Affected by disease
4 Liver Liver Lobule Hepatocytes Affected by disease
5 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
6 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Liver Cirrhosis

Articles related to Liver Cirrhosis:

(show top 50) (show all 48875)
# Title Authors PMID Year
1
Mutation of human keratin 18 in association with cryptogenic cirrhosis. 6 54 61
9011570 1997
2
Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies. 6 54
12724528 2003
3
Keratin 8 mutations in patients with cryptogenic liver disease. 6 54
11372009 2001
4
Effect of medications after cardiac surgery on long-term outcomes in patients with cirrhosis. 61 42
33592816 2021
5
Curative effects of traditional Chinese medicine on liver fibrosis: A protocol for a systematic review and meta-analysis. 42
33655924 2021
6
Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study. 42
33761674 2021
7
Relationship between the expression of IP-10 and IP-10 mRNA in peripheral blood and HBV DNA level in patients with cirrhosis. 54 61
20525556 2010
8
Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. 61 54
20428787 2010
9
The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt. 54 61
20189618 2010
10
Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. 54 61
19920809 2010
11
Hemodynamic effects of chronic smoking in liver cirrhosis: a role for adrenomedullin. 54 61
20216319 2010
12
Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. 61 54
19582578 2010
13
Splanchnic concentrations and postprandial release of visceral adipokines. 54 61
19913846 2010
14
Aquaporin-2 urinary excretion in cirrhosis: relationship to vasopressin and nitric oxide. 54 61
19495975 2010
15
Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. 54 61
20102356 2010
16
Hepatic osteodystrophy and liver cirrhosis. 61 54
20355242 2010
17
Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers. 54 61
20357999 2010
18
Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma. 61 54
20346216 2010
19
Alpha-fetoprotein gene polymorphisms and risk of HCC and cirrhosis. 54 61
19968979 2010
20
Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. 54 61
20350877 2010
21
Utilization of platelet count spleen diameter ratio in predicting the presence of esophageal varices in patients with cirrhosis. 61 54
19593164 2010
22
Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume. 61 54
19406586 2010
23
[Relationship between quality of life and basic syndromes of traditional Chinese medicine in patients with posthepatitic cirrhosis]. 61 54
20082755 2010
24
Increased bactericidal/permeability increasing protein in patients with cirrhosis. 61 54
19765220 2010
25
[Expressions of MDM2 and MMP-7 in normal liver, cirrhosis, hepatocellular carcinoma tissues]. 54 61
20128976 2010
26
Hepatitis B virus load in serum does not reflect histologic activity in patients with decompensated cirrhosis. 54 61
19804841 2010
27
Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B. 54 61
19793171 2010
28
Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging. 61 54
20118733 2010
29
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. 61 54
19877168 2010
30
Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. 61 54
19864937 2010
31
[Monitoring patients with chronic hepatitis during and after therapy]. 61 54
20198895 2009
32
Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. 54 61
19897681 2009
33
Severe sepsis in cirrhosis. 54 61
19885876 2009
34
Comparison of the effect of BCAA granules on between decompensated and compensated cirrhosis. 61 54
20214224 2009
35
IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. 61 54
19797428 2009
36
Resolution of preoperative portal vein thrombosis after administration of antithrombin III in living donor liver transplantation: case report. 61 54
19917415 2009
37
A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis. 61 54
19676133 2009
38
Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. 54 61
19243500 2009
39
Correlation of routinely used coagulation parameters and presence of portal vein thrombosis in patients with liver cirrhosis. 61 54
19619258 2009
40
Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. 61 54
19608867 2009
41
Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. 61 54
19642174 2009
42
Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases. 54 61
19294419 2009
43
[Analysis of prognostic factors for patients with acute-on-chronic liver failure]. 54 61
19719920 2009
44
Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma. 61 54
19760951 2009
45
[Comparison of the serum proteomes of pathological stages during hepatocarcinogenesis]. 61 54
19912687 2009
46
Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. 61 54
19413694 2009
47
Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. 54 61
19365625 2009
48
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. 61 54
19201777 2009
49
Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis. 61 54
19478697 2009
50
Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. 61 54
19207581 2009

Variations for Liver Cirrhosis

ClinVar genetic disease variations for Liver Cirrhosis:

6 (show all 13)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KRT8 NM_002273.4(KRT8):c.160T>C (p.Tyr54His) SNV Pathogenic, risk factor 14631 rs57749775 GRCh37: 12:53298606-53298606
GRCh38: 12:52904822-52904822
2 KRT8 NM_002273.4(KRT8):c.1202+1G>A SNV Pathogenic 1032045 GRCh37: 12:53292462-53292462
GRCh38: 12:52898678-52898678
3 KRT8 NM_002273.4(KRT8):c.184G>T (p.Gly62Cys) SNV Pathogenic 14630 rs11554495 GRCh37: 12:53298582-53298582
GRCh38: 12:52904798-52904798
4 LOC106096416 , KRT18 , KRT8 NM_000224.3(KRT18):c.383A>T (p.His128Leu) SNV Pathogenic 14585 rs57758506 GRCh37: 12:53343340-53343340
GRCh38: 12:52949556-52949556
5 FARSB NM_005687.5(FARSB):c.1381A>C (p.Thr461Pro) SNV Pathogenic 545642 rs1396171148 GRCh37: 2:223478611-223478611
GRCh38: 2:222613892-222613892
6 FARSB NM_005687.5(FARSB):c.784A>G (p.Lys262Glu) SNV Pathogenic 545655 rs1553554543 GRCh37: 2:223496325-223496325
GRCh38: 2:222631606-222631606
7 FARSB NM_005687.5(FARSB):c.1202G>A (p.Arg401Gln) SNV Pathogenic 545664 rs1553553086 GRCh37: 2:223488418-223488418
GRCh38: 2:222623699-222623699
8 FARSB NM_005687.5(FARSB):c.755T>C (p.Phe252Ser) SNV Pathogenic 545694 rs1466642025 GRCh37: 2:223496354-223496354
GRCh38: 2:222631635-222631635
9 FARSB NM_005687.5(FARSB):c.226T>C (p.Cys76Arg) SNV Pathogenic 545695 rs1419129874 GRCh37: 2:223507613-223507613
GRCh38: 2:222642894-222642894
10 LOC106096416 , KRT18 , KRT8 NM_000224.3(KRT18):c.383A>T (p.His128Leu) SNV risk factor 14585 rs57758506 GRCh37: 12:53343340-53343340
GRCh38: 12:52949556-52949556
11 KRT8 NM_002273.4(KRT8):c.184G>T (p.Gly62Cys) SNV risk factor 14630 rs11554495 GRCh37: 12:53298582-53298582
GRCh38: 12:52904798-52904798
12 LOC106096416 , KRT18 , KRT8 NM_000224.3(KRT18):c.206G>C (p.Gly69Ala) SNV Uncertain significance 1029724 GRCh37: 12:53343163-53343163
GRCh38: 12:52949379-52949379
13 LOC106096416 , KRT18 NM_000224.3(KRT18):c.541G>A (p.Asp181Asn) SNV Uncertain significance 1029725 GRCh37: 12:53344574-53344574
GRCh38: 12:52950790-52950790

Copy number variations for Liver Cirrhosis from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 210504 6 30400000 36600000 Copy number C4B Liver cirrhosis

Expression for Liver Cirrhosis

Search GEO for disease gene expression data for Liver Cirrhosis.

Pathways for Liver Cirrhosis

Pathways related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.05 SERPINA1 HGF ALB AFP
2 10.78 F2 ALB AFP
3 10.23 MEG3 HOTAIR

GO Terms for Liver Cirrhosis

Cellular components related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.46 SERPINA1 F2 ALB AFP
2 extracellular space GO:0005615 9.32 SERPINA1 KRT18 IFNA1 HGF HFE GPT
3 platelet alpha granule lumen GO:0031093 9.13 SERPINA1 HGF ALB

Biological processes related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.26 SERPINA1 F2 ALB AFP
2 hepatocyte apoptotic process GO:0097284 9.16 KRT8 KRT18
3 acute-phase response GO:0006953 8.8 SERPINA1 HFE F2

Sources for Liver Cirrhosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....